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Abstract
Background: Cancer stem cells are a chemotherapy-resistant population capable of self-renewal and of regenerating the
bulk tumor, thereby causing relapse and patient death. Ewing’s sarcoma, the second most common form of bone tumor in
adolescents and young adults, follows a clinical pattern consistent with the Cancer Stem Cell model – remission is easily
achieved, even for patients with metastatic disease, but relapse remains frequent and is usually fatal.
Methodology/Principal Findings: We have isolated a subpopulation of Ewing’s sarcoma cells, from both human cell lines
and human xenografts grown in immune deficient mice, which express high aldehyde dehydrogenase (ALDH
high) activity
and are enriched for clonogenicity, sphere-formation, and tumor initiation. The ALDH
high cells are resistant to chemotherapy
in vitro, but this can be overcome by the ATP binding cassette transport protein inhibitor, verapamil. Importantly, these cells
are not resistant to YK-4-279, a small molecule inhibitor of EWS-FLI1 that is selectively toxic to Ewing’s sarcoma cells both in
vitro and in vivo.
Conclusions/Significance: Ewing’s sarcoma contains an ALDH
high stem-like population of chemotherapy-resistant cells that
retain sensitivity to EWS-FLI1 inhibition. Inhibiting the EWS-FLI1 oncoprotein may prove to be an effective means of
improving patient outcomes by targeting Ewing’s sarcoma stem cells that survive standard chemotherapy.
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Introduction
Ewing sarcoma family tumors (ESFT) are the second most
common bone tumor in children and young adults. ESFT initially
responds quite well to cytotoxic chemotherapy, but 30% of
patients presenting with localized tumors develop recurrent disease
and 65–80% of patients with metastatic ESFT die within 5 years of
diagnosis [1,2,3]. The cancer stem cell (CSC) hypothesis provides
a framework for explaining the discrepancy between response of
ESFT to therapy and the poor survival rate. The origin of CSCs
remains controversial, but whether they are derived directly from
normal tissue stem cells, or from differentiated cells that have
acquired stem cell properties through genetic mutations, these
cells, like normal stem cells, can undergo asymmetric division and
are capable of self renewal as well as giving rise to a population of
differentiated tumor cells. CSCs have been identified in many
hematologic and solid tumors, including both acute and chronic
leukemias, brain tumors, breast cancer, and colon cancer [4,5,6,7].
CSCs are postulated to be resistant to standard cytotoxic
chemotherapeutic agents both in vitro and in vivo, and this
resistance is postulated to be the major cause of treatment failure,
as the surviving reservoir of stem cells repopulates the tumor
leading to relapse. Nevertheless, not every tumor type adheres to
the stem cell model [8]. Thus, there is an urgent need to identify
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13943and fully characterize ESFT stem cells, and to develop therapeutic
approaches to target these cells and improve the survival of
patients with recurrent or metastatic disease.
In 95% of cases, ESFT is associated with a translocation
between the central exons of the EWS gene located on
chromosome 22 and the central exons of an ets family gene;
either FLI1 located on chromosome 11, or ERG located on
chromosome 21 [9]. The resulting fusion protein acts as an
aberrant transcription factor regulating genes involved in trans-
formation. The EWS-FLI1 fusion protein is an excellent candidate
for targeted therapy as its expression is limited to tumor cells and is
crucial for initiation and maintenance of the tumor. Reducing
EWS-FLI1 expression using antisense oligonucleotides or siRNA
in cell lines results in decreased tumorigenicity both in vitro and in
vivo [10,11,12]. Moreover, transduction of mesenchymal stem cells
with EWS-FLI1 causes the development of tumors with an ESFT
phenotype [13]. The mechanism by which EWS-FLI1 mediates
neoplastic transformation is poorly understood. EWS-FLI1 has
transcriptional regulatory activity, and a number of target genes
have been identified that may play a role in neoplastic
transformation [14,15,16,17]. In addition to this activity, RNA
helicase A (RHA) physically interacts with EWS-FLI1 and
modulates oncogenesis, suggesting that this interaction is a
promising therapeutic target [18]. We have developed a novel
small molecule, YK-4-279, that inhibits the EWS-FLI1/RHA
interaction, inducing apoptosis in ESFT cell lines and xenografts
[19].
Aldehyde dehydrogenase (ALDH) has been proposed to be a
marker of both normal and cancer stem cells [20] and has been
used to identify CSC from colon, breast, and lung cancers, among
others [21,22,23]. We have identified a CSC population in ESFT
cell lines and xenografts based on high expression of ALDH.
These cells fulfill the in vitro and in vivo criteria for stem cell activity
including the ability to reconstitute a heterogeneous population,
sphere- and colony-forming activity, and the ability to form tumors
in immune deficient mice. We also found these cells to express
high levels of stem cell-associated genes such as bmi-1, nanog, and
oct-4. Moreover, these cells are relatively resistant to cytotoxic
agents such as doxorubicin and etoposide. We then demonstrated
that these cells express EWS-FLI1 and that, in contrast to
cytotoxic drugs, they retain sensitivity to the small molecule
inhibitor YK-4-279. Thus, our study utilizes a novel, molecularly
targeted approach to target ESFT stem cells and bypass their
relative chemoresistance, which may lead to new therapies to
improve the survival of ESFT patients.
Results
ESFT cell lines and xenografts contain a small population
of cells with high expression of aldehyde dehydrogenase
ALDH is one of a family of enzymes involved in several
detoxifying pathways [24]. Elevated ALDH expression has
recently been used to identify a rare stem cell-like population in
several tumor types, including leukemia, brain, colon and breast
cancer [25]. To determine whether ESFT cell lines contain a high
ALDH expressing stem cell-like population, we used the Aldefluor
reagent to test ALDH activity in five ESFT cell lines (TC71,
MHH-ES, SK-ES-1, A4573, and RD-ES). Each of these cell lines
contains a population of cells with fluorescence that is inhibited by
the ALDH inhibitor diethylaminobenzaldehyde (DEAB; Figure 1).
We observed a distribution of ALDH activity across the
population of ESFT cells. We isolated the cells with the highest
Figure 1. Aldehyde dehydrogenase (ALDH) expression in ESFT cell lines. The indicated cell lines were treated with Aldefluor reagent alone
(top) or in the presence of the ALDH inhibitor DEAB (bottom), and then analyzed by FACS. Each cell line has an Aldefluor bright cell population that is
undetectable in the presence of DEAB. In each panel, the box indicates a typical gate, containing approximately 2% of the cells, defined as ALDH
high
and used for subsequent experiments. Of note, these cells also have low side scatter. These sorting experiments have been performed a minimum of
three times on each cell line.
doi:10.1371/journal.pone.0013943.g001
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high and
ALDH
low) to test our hypothesis that although all cells express
some amount of ALDH (and therefore will have DEAB-inhibitable
fluorescence), the cells with the highest ALDH activity (ALDH
high)
are enriched for a stem cell phenotype. To determine the purity of
our sorted cells, we isolated both ALDH
high and ALDH
low cells
(Figure 2). Viable cells, as determined by exclusion of propidium
iodide, were then reanalyzed using the original Aldefluor channel.
This analysis revealed a sorting efficiency of .98% (Figure 2).
In addition to cell lines, we also analyzed single cell suspensions
prepared from three different early-passage ESFT xenografts of
primary human tumors (generous gifts from Drs. C. Khanna and
L. Helman, NIH), and we detected a similar distribution of ALDH
expression in these cells (Figure 3). Initially, viable cells were
isolated from the single cell suspension based forward scatter, side
scatter, and exclusion of PI (Figure 3A, gate R0). Cell suspensions
were stained with the Aldefluor reagent and sorted (Figure 3B).
ALDH
low (Figure 3B, Gate R4) and ALDH
high (Figure 3B, Gate
R3) cells were isolated for further analysis. As with the cell lines,
DEAB served as a negative control (Figure 3C). To exclude
contamination with murine cells, single cell suspensions were
incubated with the Aldefluor reagent, and then with an antibody
against the murine major histocompatibility complex (MHC)
proteinH2Kd. FACS was used to eliminate the cells expressing
mouse MHC (which accounted for 2.5% of the total; Figure 3D,
gate R2; Figure 3E shows the effect of including DEAB).
Subsequent sorting for ALDH activity (Figure 3F) gave results
indistinguishable from experiments from which murine cells were
not excluded. An ALDH
high population was also seen in three
other early passage xenografts (Figures 3G, H, and I, with DEAB
control in J, K, and L).
Because ESFTs are diagnosed by needle biopsy and not resected
until after administration of neoadjuvant chemotherapy, adequate
numbers of cells from newly diagnosed tumors could not be
obtained to verify these findings in primary patient samples;
however, we performed immunohistochemistry to evaluate
ALDH1 expression in a panel of twenty-two biopsy specimens
obtained from a total of 10 patients with ESFT (mean 2.2 biopsy
samples per patient, with a range of 1–4). We found variable
ALDH protein expression in each specimen, with a gradient of
staining, including cells lacking expression, cells with modest
amounts of staining, and a small minority with very high intensity
staining (Figure 4A), consistent with our flow cytometry results
from cell lines and xenografts. Expression was quantified using the
FRIDA image analysis software package. An average of 0.7%
(61.3) of cells stained for ALDH, and 99.3% (61.3) of cells were
negative (p,0.0001). Staining adjacent sections with CD99, a
marker for ESFT cells (Figure 4B), confirmed that the ALDH-
positive cells were indeed tumor cells.
ALDH
high cells are enriched for clonogenic and sphere
forming activity
Clonogenic activity in soft agar has been proposed as an in vitro
measure of tumor initiating activity, the defining characteristic of
cancer stem cells. We therefore compared the ability of the
ALDH
high cells and ALDH
low cells to form colonies on soft agar.
The ALDH
high and ALDH
low subpopulations of TC71 and
MHH-ES cells were collected, plated on soft agar, and allowed to
grow for two weeks. The ALDH
high cells gave rise to significantly
more colonies than did the ALDH
low cells (p=0.012; Figure 5A).
The colonies formed by the ALDH
high cells were also substantially
larger than the few colonies formed from ALDH
low cells – 49.3%
of the colonies formed by ALDH
high cells were larger than 150 mm
and 30.1% were larger than 200 mm, while only 13.1% of the
colonies formed by the ALDH
low cells were larger than 150 mm
and none were larger than 200 mm.
The ability to form spherical aggregates (‘‘sarcospheres’’) when
cultured under non-adherent conditions is also a characteristic of
cancer stem cells. ALDH
high and ALDH
low cells were isolated
from the TC71 cell line, resuspended in supplemented Mesencult
media, and plated on ultra low attachment plates. After one week,
spherical aggregates $16 cells were counted. As anticipated,
ALDH
high cells gave rise to approximately 4–5-fold more spheres
than the ALDH
low cells, a statistically significant difference
(p=0.0015; Figure 5B). Similar results were found using MHH-
ES, SK-ES-1, and A4573 cells as well (data not shown).
When we assayed the clonogenic activity (in soft agar) and
sphere forming ability (in Mesencult) of cells isolated from one of
the primary ESFT xenografts described above, ALDH
high cells
gave rise to significantly more colonies and spheres than the
ALDH
low cells (p,0.005 for sphere formation; Figure 5C and data
not shown); in fact, the ALDH
low subpopulation from the
xenograft was completely devoid of sphere forming activity,
although the initial viability of both cell populations, as assessed by
Trypan blue exclusion, was similar. The sphere formation assay
was also conducted with cells from another xenograft (Figure 5D),
sorted to exclude contaminating murine cells with high levels of
ALDH expression (see Figure 3). Exclusion of these contaminating
cells did not alter the differential sphere forming activity (Figure 5).
In this case, 5,000 cells were plated in triplicate. The ALDH
high
cells generated 34.6762.4 spheres per well, significantly more than
the unsorted cells (11.6760.88; p=0.0008) or the ALDH
low cells
(0.66760.33; p=0.0002).
Finally, we investigated whether growing TC71 cells as
sarcospheres would enrich for cells with high levels of ALDH
expression. The ALDH
high population (in this case defined as the
cells with the highest 3% of ALDH activity; Figure 6) from
adherent TC71 cells was collected and plated under nonadherent
conditions in Mesencult as described above. The resulting
sarcospheres were collected, disaggregated, and replated in
Mesencult under nonadherent conditions. After 5 such passages,
cells were analyzed by the Aldefluor assay. In the primary
adherent population, ALDH
high cells represented only 3% of the
population, however after the 5
th passage, cells with an amount of
ALDH activity, as determined by fluorescence intensity, equiva-
lent to the starting cells constituted 27% of the total (Figure 6), a 9-
fold increase. Similar results were seen with SK-ES-1 cells and
A4573 cells (data not shown).
ALDH
high but not ALDH
low cells are capable of
reconstituting a heterogeneous population in vitro
A defining property of stem cells is their ability to undergo
asymmetric division, resulting in both a self renewing population
of stem cells and a more differentiated non-stem cell population.
To determine whether ALDH
high cells are capable of regenerating
such a heterogeneous population, ALDH
high and ALDH
low cells
were isolated from the RD-ES cell line and were cultured
separately at similar density. After two weeks, we analyzed the
cultured populations using the Aldefluor assay. The ALDH
high
cells gave a similar profile to the parent population, with the
majority of cells ALDH
low and only a small fraction being
ALDH
high. In contrast, ALDH
low cells were unable to generate
ALDH
high cells (Figure 7). Similar results were obtained with the
TC71 cell line (data not shown). The ability of the ALDH
high cells
to re-generate a heterogeneous population of cells supports the
hypothesis that high ALDH activity identifies a population
enriched for ESFT stem cells.
EWS-FLI Inhibitor Targets ESSC
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high cells are enriched for expression of the ‘‘stem
cell genes’’
We investigated whether ALDH
high cells are enriched for
expression of genes that have been postulated to play key roles in
stem cell biology, such as the polycomb group gene bmi-1 [26], the
POU DNA binding domain-containing gene oct-4 [27], and nanog,
a key regulator of stem cell pluripotency [28], relative to the
ALDH
low population. We isolated the ALDH
high and ALDH
low
subpopulations from TC71 cells and measured oct-4 expression
using primers specifically designed to exclude the numerous oct-4
pseudogenes [29]. Qualitative PCR shows significant oct-4
expression in the ALDH
high population, with less expression in
the unsorted cells, and only minimal expression in the ALDH
low
cells (Figure 8A). We confirmed this differential expression using
immunocytochemistry. ALDH
high and ALDH
low TC71 cells were
subjected to immunocytochemistry using an anti-Oct-4 antibody.
Most of the ALDH
high cells were stained with the antibody, but no
staining was seen in the ALDH
low cells (Figure 8B). We
investigated bmi-1 and nanog RNA expression using quantitative
RT-PCR, with b2-microglobulin expression as a control. We
detected a 12.4-fold increase in bmi-1 mRNA levels in ALDH
high
compared to ALDH
low cells and a 14.7-fold increase in nanog
mRNA(Figure 8C).
ALDH
high cells exhibit tumor initiating activity in vivo
In addition to self renewal, the other defining characteristic of
a cancer stem cell is tumor initiation. To investigate the
tumorigenicity of ALDH
high cells in vivo, we isolated ALDH
high
and ALDH
low TC71 cells and injected them subcutaneously in
the flanks of individual NOD/SCID/IL-2Rc
null (NOG-SCID)
mice. Unsorted cells were injected as a control. After 6–10 weeks,
tumors were detected in the flank region with an average size of
10612 mm. Tumor formation was seen after injection of as few
as 160 ALDH
high cells (Table 1). In contrast, only 9 out of 13 of
the mice injected with 800,000 ALDH
low cells and none of the
mice injected with 80,000 or fewer ALDH
low cells developed a
tumor, suggesting that this population was relatively depleted of
tumor initiating cells. Injections of 800,000 unsorted cells reliably
caused tumor formation, and 3 of 7 mice injected with 80,000
unsorted cells also developed a tumor. Thus, in TC71 cells,
tumor initiating cells represent approximately 0.6% of the
ALDH
high population and less than 10
25 of the ALDH
low
population. Similar data were obtained using MHH-ES cells
(Table 1). Importantly, tumors that arose from ALDH
high cells
from both cell lines could be serially transplanted into secondary
and tertiary recipients, consistent with the presence of ESSC in
this population. Gross tumor appearance and histology were
similar for tumors arising from the unsorted cells, the ALDH
low
cells and the ALDH
high cells (Figure 9). Immunohistochemistry
demonstrated that only a small minority (,1%) of tumor cells
expressed a high level of ALDH, even in tumors that arose from
implantation of purified ALDH
high cells (Figure 9C), supporting
the hypothesis that these represent true cancer stem cells, able to
generate serially-transplantable tumors that contain mostly
ALDH
low non-stem cells.
ALDH provides superior enrichment for stem cells
compared with CD133
The cell surface antigen CD133 has been proposed to be a stem
cell marker, and CD133-positive ESFT cells have tumor initiating
activity [30]. We therefore compared clonogenic and tumor
initiating activities of our ALDH
high cells with those of CD133-
positive cells. We isolated ALDH
high and CD133-positive TC71
cells by FACS (Figure 5E) and cultured 1000 cells/well of each
population on ultra low attachment plates supplemented with
Mesencult to compare their sphere forming ability. After one week
in culture, although the CD133-positive cells did give rise to more
spheres than the CD133-negative/ALDH
low cells (p=0.001;
Figure 5F), the ALDH
high cells gave rise to significantly more
sarcospheres than the CD133-positive cells (p=0.015). In addition
to clonogenic activity, we also compared tumor initiating activity
of CD133-positive and ALDH
high cells. Although as few as 800
CD133-positive cells were sufficient to give rise to tumors in
NOG-SCID mice, unlike the ALDH
high cells, injection of 160
CD133-positive cells did not result in tumor formation (Table 1).
Similar results were seen using MHH-ES cells (Table 1). Thus,
both in vitro and in vivo assays demonstrate that, in both TC71 and
MHH-ES cells, the ALDH
high population of cells is more enriched
for stem cell activity than the CD133-positive cells.
ALDH
high cells are resistant to chemotherapy
The cancer stem cell hypothesis proposes that the discrepancy
between treatment response and patient survival noted in most
cancer types reflects an inherent resistance of the cancer stem cells
to chemotherapy. We therefore investigated whether ALDH
high
ESFT cells are resistant to chemotherapy, as would be expected if
this population is enriched for cancer stem cells. ALDH
high and
ALDH
low cells were isolated from TC71, A4357, MHH-ES, SK-
ES-1, and RD-ES cell lines and incubated with increasing doses of
doxorubicin, one of the most important chemotherapy drugs for
the treatment of ESFT. Cell survival was evaluated by counting
viable cells remaining after 48 hours. In all 5 cell lines, ALDH
low
cells showed the same dose dependent decrease in cell viability
seen with the unsorted cells, whereas in 4 of the 5 lines, the
ALDH
high cells were significantly more resistant to doxorubicin
over the dose range tested (Figure 10 left panels). Similar results
were obtained using etoposide in place of doxorubicin (data not
shown).
One of the proposed mechanisms by which cancer stem cells
resist chemotherapy is by enhanced expression of ATP-binding
cassette (ABC) transport proteins, which are responsible for drug
efflux. Higher expression of ABC transport proteins in stem cells
compared to non-stem cells results in relative resistance of the stem
cells to the toxic effects of chemotherapy drugs compared with the
bulk population. We address this aspect of stem cells using a
functional evaluation of fluorescent dye efflux. ALDH
high and
ALDH
low cells isolated from the TC71 cell line were incubated
with Hoechst 33342 for 45 minutes, followed by a 45 minute
wash-out. After the wash-out, cells were photographed under UV
light and the relative fluorescence units (RFU) quantified. This
assay revealed a significant increase in dye efflux by the ALDH
high
cells compared with the ALDH
low cells. The ALDH
high population
Figure 2. Evaluation of sorting efficiency. TC71 cells were incubated with the Aldefluor reagent and sorted as described (A). Viable (based on PI
exclusion) ALDH
low and ALDH
high cells were isolated as indicated by the arrows (B). The viable cells from each population (as well as the entire
population, in the center panel) were analyzed for Aldefluor-related fluorescence (C), and an overlay of the resulting histograms shows no
appreciable overlap (D), demonstrating a sorting efficiency of .98%. This check was performed three times, and the data presented are from a
representative experiment.
doi:10.1371/journal.pone.0013943.g002
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13943Figure 3. ALDH expression in primary human ESFT xenografts. Single cell suspensions were made from each of four early passage primary
human ESFT xenografts. (A) The first step of purification was isolation of viable cells based on scatter and PI exclusion (enclosed in gate R0). Viable
cells were stained with Aldefluor without (B) or with (C) DEAB. To exclude contamination with murine cells, single cell suspensions were incubated
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the ALDH
low cells (Figure 11A). This difference is highly
statistically significant (p=0.0005).
The calcium channel blocker, verapamil, blocks the activity of
ABC transporter proteins, and is used to corroborate ABC
transporter function [31]. If differential expression of these drug
pumps mediates the relative resistance of ALDH
high cells to
cytotoxic chemotherapy, then this resistance should be reversed by
concurrent treatment with verapamil. To test this hypothesis,
ALDH
high and ALDH
low cells isolated from the TC71 cell line
were incubated for 48 hours with 500 nM doxorubicin with or
without 10 mM verapamil. The doxorubicin killed 55% of the
unsorted cells (p=0.0016 compared with untreated controls), and
the addition of verapamil significantly augmented this toxicity –
killing 40% more cells (p=0.0002). The ALDH
low cells were even
more sensitive to doxorubicin, with 500 nM killing 85% of the
cells in 48 hours (p,0.0001 for the difference between control and
doxorubicin-treated), and the addition of verapamil did not cause
a significant increase in the efficacy of doxorubicin against this
population. As previously observed, although doxorubicin alone
did not affect the survival of the ALDH
high cells, there was a
statistically significant 80% decrease in the viability of ALDH
high
cells treated with both 10 mM verapamil and 500 nM doxorubicin
(p,0.0001 between doxorubicin alone and doxorubicin plus
verapamil; Figure 11B).
Standard cytotoxic chemotherapy drugs do not inhibit
clonogenic activity of ALDH
high cells
Our in vivo tumor initiation data demonstrate that only a
fraction of the ALDH
high cells have tumor initiating (stem cell)
activity. The data presented above demonstrate that ALDH
high
cells are relatively resistant to chemotherapy, but they do not
prove that the resistant cells are the ones with the stem cell
phenotype. The cancer stem cell hypothesis predicts that the
chemotherapy-resistant ALDH
high cells should retain stem cell
activity. To test this, we assessed the clonogenic activity of
ALDH
high and ALDH
low cells treated with doxorubicin. ALDH-
high and ALDH
low TC71 cells were seeded separately on soft agar
and treated with varying concentrations of doxorubicin. After two
weeks, colonies were stained and counted in individual wells. At
each doxorubicin dose we detected both larger and more
numerous colonies arising from ALDH
high compared with
ALDH
low cells (Figure 12A). Moreover, although ALDH
low cells
showed a dose dependent decrease in clonogenicity and inhibition
of almost all colony growth by 200 nM doxorubicin, the
clonogenic activity of ALDH
high cells was unaffected by low doses
of the drug and decreased only modestly in response to 200 nM
doxorubicin (Figure 12B). These data suggest that the ALDH
high
cells which resist the cytotoxic effects of doxorubicin retain
clonogenic activity.
ALDH
high cells retain sensitivity to EWS-FLI1 inhibition
We next tested our hypothesis that inhibition of EWS-FLI1
activity is toxic to ESFT CSC that are resistant to standard
cytotoxic chemotherapy. One critical function of EWS-FLI1
involves a physical interaction with RNA helicase A (RHA). A
small molecule, YK-4-279, has been developed to specifically
disrupt this interaction [19]. This compound induces apoptosis in
ESFT cells both in vivo and in vitro. We investigated whether YK-4-
279 is toxic to the ALDH
high subpopulation of ESFT cells. In
order for YK-4-279 to have an effect on ALDH
high cells, these cells
must express EWS-FLI1. Using RT-PCR we confirmed EWS-
FLI1 expression in ALDH
high cells (Figure 11C). To assess the
sensitivity of ESFT CSC to YK-4-279, ALDH
high and ALDH
low
cells were isolated from RD-ES, MHH-ES, TC71, SK-ES-1, and
A4573. Isolated cell populations were incubated with increasing
doses of either YK-4-279 or doxorubicin. Cell survival was
evaluated by counting viable cells remaining after 48 hours using
the Trypan blue exclusion assay. The ALDH
high and ALDH
low
cells showed identical dose dependent decreases in cell viability
when treated with YK-4-279 (Figure 10, right panels). In contrast,
Figure 4. ALDH expression in primary ESFT biopsy samples. (A).
Representative section of a primary Ewing’s sarcoma at low power
(206) showing expression of ALDH1, as revealed by immunohisto-
chemistry. The red triangle indicates the cell with the strongest staining.
(B). An adjacent section from the same biopsy specimen demonstrating
CD99 expression. In both images, positive staining is indicated by the
brown color. Samples were counterstained with hematoxylin to show
general tumor histology.
doi:10.1371/journal.pone.0013943.g004
with an antibody against murine MHC after Aldefluor treatment without (D) or with (E) DEAB. FACS was used to eliminate the cells expressing mouse
MHC (gate R2 in panels D and E), and cells were sorted for ALDH activity (F). In panel F, gate R3 is the ALDH
high cells and gate R4 is the ALDH
low cells.
Three other xenografts were also analyzed by Aldefluor without (G, H, I) or with (J, K, L) DEAB.
doi:10.1371/journal.pone.0013943.g003
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PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13943Figure 5. Clonogenic and sphere forming activity of ALDH
high cells. A) ALDH
high and ALDH
low TC71 cells were plated in soft agar at 1000
cells/well. Data from 3 independent experiments represent average colony count/well after 14 days. B) ALDH
high and ALDH
low TC71 cells were plated
in Mesencult at 1000 cells/well for 7 days. Data shown is the average sphere count from a representative experiment performed in triplicate wells. C)
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high cells obtained from TC71, SK-ES, RD-ES, and MHH-
ES were relatively resistant to doxorubicin when compared to
ALDH
low cells (Figure 10, left panels).
To fully assess whether YK-4-279 eradicates ESFT stem cell
activity, ALDH
high and ALDH
low TC71cells were plated in soft
agar in the presence or absence of YK-4-279. At doses as low as
3 mM, the clonogenic activity of the ALDH
high cells was inhibited.
One week following treatment we detected a dose dependent
decrease in both the number and size of colonies from ALDH
high
and ALDH
low cells, and by two weeks almost no viable colonies
were detected, only clumps of cell debris (Figure 12C and D).
Thus, ALDH
high cells retain sensitivity to YK-4-279 induced
EWS-FLI1 inhibition, as reflected by both direct cytotoxicity and
by loss of clonogenic activity. Notably, treatment of ALDH
high
cells with doxorubicin does not eliminate clonogenic activity, but
treating these cells with YK-4-279 does (Figure 12).
Discussion
ESFT is a chemotherapy-sensitive cancer, and even patients
who present with metastatic disease commonly achieve remission.
Despite this, 25% of patients who present with a localized tumor
and 70% of patients who present with metastases will develop a
recurrence and ultimately die of their disease [1,2,3]. The presence
of chemotherapy-resistant CSC has been put forth as one
explanation for this discrepancy between response to treatment
and patient survival. Not every tumor type has been shown to
follow the CSC model [8], so we and others have sought evidence
for the existence of a Ewing’s sarcoma stem cell. Our work has
demonstrated that the subpopulation of ESFT cells that express
the highest levels of ALDH have several characteristics of stem
cells, including the capacity to generate a heterogeneous
population, in vitro clonogenic activity and in vivo tumorigenic
activity. As predicted, these cells are resistant to standard cytotoxic
chemotherapy; however, we have demonstrated that these cells
retain sensitivity to a small molecule inhibitor of EWS-FLI1.
Several approaches have been taken to identify CSC from other
tumor types, including evaluation of immunophenotype and
various functional assays. We chose to pursue ALDH expression
because high expression of ALDH is thought to provide a survival
advantage in a toxic cellular microenvironment, and studies have
demonstrated high ALDH expression in CSC from breast and
colorectal carcinomas. No single assay is likely to yield a pure
population of CSC, but our data demonstrate that as few as 160
ALDH
high cells can form a tumor in immune deficient mice
suggests that ALDH expression allows substantial enrichment of
this population.
Suva et al recently showed that CD133 expression marks a
population of Ewing’s sarcoma cells with tumor initiating activity
[30]. Our experiments extend that initial observation of a ‘stem-
like’ population in Ewing’s sarcoma in several important ways and
have identified a more consistent tumor-initiating cell population.
Although both isolation methods (CD133 expression and Alde-
fluor) result in a population enriched for cells able to reconstitute
tumors when implanted in immunodeficient mice, our work
demonstrates that the unique ALDH
high, low side scatter
population of cells is more enriched for cells with clonogenic
activity in vitro and tumor initiating activity in vivo than the
CD133-positive cells. In addition, the ALDH
high population of
cells expresses high levels of several genes associated with a stem
cell phenotype (bmi-1, oct-4, and nanog) and can reconstitute the
heterogeneous parental population in vitro and in vivo. Our most
clinically important observation, distinct from prior publications, is
that the ALDH
high population is relatively resistant to cytotoxic
chemotherapeutic agents. Interestingly, Jiang et al. recently
reported that there is almost no correlation between CD133
expression and resistance to chemotherapy in ESFT cell lines
([32]). We demonstrated that, unlike CD133+ cells, in 4 of the 5
cell lines tested, ALDH
high cells are resistant to both doxorubicin
and etoposide. Intriguingly, the one cell line that did not show
relative resistance of ALDH
high cells to doxorubicin, A4573, has
previously been demonstrated to be more relatively more resistant
to this agent than other ESFT cell lines [33]. Most important in
our findings is that, in contrast to the differential resistance of
ALDH
high cells to standard cytotoxic chemotherapeutic agents
compared with ALDH
low cells, ALDH
high cells retain sensitivity to
the EWS-FLI1 targeted inhibitor, YK-4-279. This not only
identifies a potential clinical strategy to prevent tumor recurrence,
but also suggests that ESFT repopulating cells are still dependent
on the activity of the pathognomonic tumor-associated transcrip-
tion factor EWS-FLI1. In addition to many previous publications
that validate EWS-FLI1 as a therapeutic target, we now show that
targeting EWS-FLI1 will potentially access ESFT cells that
become resistant to conventional chemotherapy.
One limitation to our work is our inability to use primary tumor
samples as a source of ALDH
high cells to confirm that such cells
isolated directly from patients have a stem cell phenotype. ESFTs
are most often diagnosed by needle biopsy and not resected until
after administration of neoadjuvant chemotherapy, such that
adequate numbers of fresh cells could not be obtained in primary
patient samples. Thus it is not possible to obtain sufficient material
from patients to verify our cell line and xenograft findings. We
have attempted to address this limitation by evaluating patient
biopsy specimens for ALDH expression using immunohistochem-
istry (Figure 4). Results of this analysis are consistent with ALDH
expression marking a stem cell population. Future studies will be
designed to evaluate the impact of the percentage of ALDH
positive cells on clinicopathologic features of the disease.
The clinical significance of CSC is their inherent resistance to
chemotherapy as CSCs from other solid tumors are chemoresis-
tant. Following chemotherapy, Dylla et al., detected enrichment of
CSC in colorectal carcinoma xenografts [34]. In squamous cell
cancers, side population cells (cells that exclude the fluorescent dye
Hoechst 33342) maintain clonogenicity in the presence of
cytotoxic drugs [35]. In another study, side population cells
isolated from primary neuroblastoma exhibited an enhanced
capacity to expel cytotoxic drugs [36]. Multiple mechanisms have
been proposed to explain the chemoresistance of CSC. The best
characterized of these is high expression of ABC transporter
proteins which mediate drug efflux [37]. ALDH itself also
Average sphere count from ALDH
high and ALDH
low cells isolated from an ESFT xenograft. 3000 cell/well in triplicate wells were cultured in Mesencult
for 14 days. Bars=SEM (D) ALDH
high and ALDH
low cells isolated from a second ESFT xenograft, this one with contaminating murine cells excluded as
shown in Figure 3 were cultured in Mesencult for 14 days in triplicate wells with 3000 cells/well. Bars=SEM. (E) MHH-ES cells were incubated with the
Aldefluor reagent followed by PE-labeled anti-CD133 and then were sorted for ALDH and CD133 expression simultaneously. Only a small number of
CD133-positive cells are seen, and these are evenly distributed across the ALDH spectrum (gate R3). (F) CD133-positive cells, ALDH
high cells, and
control cells (CD133-negative, ALDH
low) were plated in Mesencult at 1000 cells/well for 7 days. Data shown is the average sphere count from a
representative experiment performed in triplicate wells. Bars=SEM. Each experiment was performed a minimum of three times. In each panel, the p
value shows the significance of the difference between the indicated populations, as determined by a one-tailed t test.
doi:10.1371/journal.pone.0013943.g005
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enzyme for chemotherapeutic drugs such as cyclophosphamide
[38]. Our data demonstrate that ESSC are resistant to two of the
standard agents used to treat ESFT – doxorubicin and etoposide.
Our dye efflux assay suggests that ESSC have relatively higher
transport protein activity than the bulk population, and chemo-
resistance is reversed by verapamil, an inhibitor of ABC transport
proteins. Thus, drug efflux pump activity may be an important
mechanism of ESSC chemoresistance. Future investigations
will evaluate drug efflux pump protein expression in ESSC
populations.
The relatively static survival rates for patients with Ewing’s
sarcoma, especially those with metastatic disease, despite intensi-
fication of standard chemotherapy [1] suggests that novel,
biologically based treatment approaches must be developed. Our
small molecule, YK-4-279, represents a different approach to
targeted therapy for ESFT. This compound disrupts a critical
interaction between EWS-FLI1, the protein product encoded by
the fusion gene resulting from the t(11;22) translocation, and a
heterologous binding protein, RHA. Disruption of this interaction
induces apoptosis in ESFT cells [19]. Our data show that although
ESSC are resistant to standard cytotoxic agents, they retain
sensitivity to YK-4-279. Combined with evidence that YK-4-279
inhibits the growth of ESFT xenografts in mice, these data provide
support for the idea that small molecules that disrupt critical
protein-protein interactions involving EWS-FLI1 represent a
promising therapeutic approach for patients with high risk disease
for whom standard chemotherapy is inadequate.
Figure 7. Self renewal ability of ALDH
high cells. (A) RD-ES cells were incubated with Aldefluor alone (top) or in the presence of DEAB (bottom).
The ALDH
high (R2) and ALDH
low (R3) populations were isolated and cultured for 2 weeks. As described in the Methods section, these gates were
chosen to isolate the cells with the highest and lowest 2% of ALDH activity. Cells were then incubated with Aldeflour and reanalyzed by FACS. (B) The
ALDH
high cells give rise to both ALDH
high (gate R3) and ALDH
low (gate R2) populations. (C) The ALDH
low cells only regenerated an ALDH
low
population. In both panels B and C, analysis was performed without (top) or with (bottom) DEAB, just as in panel A.
doi:10.1371/journal.pone.0013943.g007
Figure 6. Passaging as sarcospheres enriches for ALDH
high cells. TC71 cells were grown under standard, adherent conditions. The cells with
the highest 3% of ALDH activity were isolated and replated in Mesencult under nonadherent conditions. The resulting sarcospheres were
disaggregated into single cells, sorted, and the ALDH
high cells replated under identical conditions. After 5 such passages, cells from disaggregated
sarcospheres were analyzed by the Aldefluor assay. The initial gate, which encompassed only 3% of the starting cells, included 27% of the cells
passaged as sarcospheres.
doi:10.1371/journal.pone.0013943.g006
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high and ALDH
low cells. TC71 cells were treated with Aldefluor, and ALDH
high, ALDH
low,
and unsorted cells were isolated. (A) Cells were analyzed for oct-4 expression by RT-PCR using primers reported by Liedtke et al to not amplify known
oct-4 pseudogenes [29]. Expression of ribosomal RNA 36B4 is shown as a positive control. No cDNA and No RT negative controls are also shown. The
lower band in the first 3 (oct-4) lanes probably represents primer dimers. (B) ALDH
high and ALDH
low TC71 cells were evaluated for Oct-4 protein
expression by immunocytochemistry. The blue color represents DAPI staining (which stains all cell nuclei), and the red staining reflects Oct-4
expression. (C) RNA from ALDHhigh and ALDHlow TC71 cells was tested for nanog and bmi-1 expression by quantitative RT-PCR. Each of these ‘‘stem
cell genes’’ was expressed at significantly higher levels in ALDH
high cells than in ALDH
low cells.
doi:10.1371/journal.pone.0013943.g008
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Cell lines and xenograft model
ESFT cell lines TC-71, MHH-ES, SK-ES-1, A4573, and RD-ES
were obtained from ATCC (Manassas, VA). Cells were cultured at
50–70% confluence in RPMI-1640 medium supplemented with
10% fetal bovine serum (Invitogen, Grand Island, NY) and 1%
penicillin/streptomycin (Quality Biological Inc., Gaithersburg,
MD). Transplantable xenografts of primary human ESFT were a
kind gift from Dr. Chand Khanna and Dr. Lee Helman (National
Institutes of Health). The creation of these xenografts was approved
by the Institutional Review Board of the National Institutes of
Health, and patients gave informed consent for their creation.
Xenografts were re-engrafted into six to eight week old NOG-SCID
mice (Jackson Laboratory, Bar Harbor, Maine; colony maintained
at JHMI). Mice were anesthetized with a single intraperitoneal dose
of 240 mg/kg Avertin (Sigma, St. Louis, MO), two 3 mm tumor
fragments were implanted adjacent to the right proximal tibia bone
after creating a small incision in overlying muscle, liquid tissue
adhesive (NEXABANDH, Abbott Laboratories, North Chicago, IL)
was applied to seal the muscle, and the skin wound was closed with
9 mm surgical clips. Mice were maintained in a pathogen-free
environment and monitored weekly for tumor growth. After 10–
12 weeks, mice were sacrificed; tumors were harvested and
prepared into single cell suspension for further experiments. All
procedures were performed according to a protocol approved by
the Johns Hopkins Animal Care and Use Committee.
To create single cell suspension, tissue samples were mechan-
ically minced with a scalpel and further dissociated in 0.25%
trypsin (Wheaton Sciences, USA). Cells were allowed to recover
overnight at 37uC and the next day were analyzed by FACS. To
eliminate cells of mouse origin, a biotin labeled mouse anti-mouse
H-2K[d] antibody (SF1-1.1, BD Pharmingen) was used at 1:200
dilution in Aldefluor assay buffer containing 2% FBS for 20
minutes on ice(Reference- Ginestier C, Dontu G, 2007). The cells
were subsequently labeled with APC-conjugated Streptavidin
(SAV-APC, eBioscience) at 0.06 mg per sample for 20 minutes
on ice and analyzed using the BD- FACSAria flow cytometer.
Aldeflour assay and Fluorescence-activated cell sorting
(FACS)
The AldefluorH assay (Stem Cell Technologies, Vancouver, BC)
was performed according to the manufacturer’s instructions.
ALDH
high cells were identified in ESFT cell lines and xenografts
by comparing the same sample with and without the ALDH
inhibitor DEAB. Cells were analyzed and sorted using FACSAria
and FACSDiva software (BD Biosciences, Franklin Lakes, NJ).
Dead cells were excluded based on light scatter characteristics and
gates were set to select the brightest and dimmest 2–3% of the
analyzed population on average. Viability of sorted cells was 55–
65% as tested by Trypan blue dye exclusion (Invitrogen) or by
exclusion of PI. In some experiments, cells were labeled with PE-
conjugated anti-human CD133/2 (Miltenyi Biotec, Auburn, CA.)
after being incubatedwithAldefluor. Samples wereincubated inthe
dark with 5 mg/ml of the antibody or the isotype control IgG for
10 min at 4uC, then washed, resuspended, and analyzed by FACS.
Immunohistochemistry
Paraffin-embedded ESFT tissue samples were deparaffinized in
xylene and rehydrated in graded alcohol and rinsed in 16 PBS.
Antigens were retrieved by boiling samples for 12 minutes in citrate
buffer, pH 6 (Invitrogen). Nonspecific binding sites were blocked
using 1 mL PBS containing 5% goat serum and 1% bovine serum
Figure 9. Analysis of tumors grown from ALDH
high ESFT cells. (A) Mice with tumors growing from ALDH
high, but not ALDH
low, MHH-ES cells
injected subcutaneously in the flank. In each case, ALDH
high cells were injected in the right flank, and ALDH
low cells were injected in the left flank. (B)
Gross appearance of resected tumors. (C) Immunohistochemical analysis of MHH-ES-derived tumors. Paraffin-embedded sections were evaluated for
ALDH expression by immunohistochemistry, and counterstained with hematoxylin to evaluate tumor histology. Tumors are comprised of small round
blue cells, as is typical of ESFT. The brown staining shows the rare ALDH-expressing tumor cells (indicated by red arrowheads), despite the fact that
the cells injected into the mouse uniformly expressed high levels of ALDH.
doi:10.1371/journal.pone.0013943.g009
Table 1. Tumor Initiating Capacity of Various Cell
Populations.
TC71 Cells MHH-ES Cells
Cell Number Cell Number
800,000 80,000 8,000 800 160 8,000 800 160
(Tumors/Mouse) (Tumors/Mouse)
Unsorted 3/3 3/7 0/5 0/5
ALDH
high 4/4 4/4 8/15 6/10 6/6 5/5 5/5 4/5
ALDH
low 9/13 0/4 0/4 0/5 0/5 0/5
CD133+ 2/2 0/2 0/3 0/5
doi:10.1371/journal.pone.0013943.t001
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humidor with monoclonal antibody to ALDH1 (1:100; BD
bioscience, clone 44), diluted with 1% goat serum, 0.2% BSA and
0.3%Triton X-100 inPBS(pH 7.4), followed by washing with PBS.
Sections were then incubated with peroxidase-conjugated second-
ary antibody (Jackson Immunoresearch Laboratories, USA) of
appropriate specificity. 3,39-diaminobenzidine (DAB, Pierce) was
used as substrate for peroxidase and counterstaining was performed
with modified Harris hematoxylin solution (Sigma). Sections were
dehydrated by passage through graded alcohol concentrations and
finally xylene. Cover slips were mounted using DPX (Sigma).
Completed immunostaining was visualized using microscopy
(Nikon E600), and photographed with digital camera (Nikon
DXM1200F; ACT-1 software).
For immunocytochemical detection of Oct4, TC71 cells were
pelleted on slides using a cytospin. Cells were fixed with 4%
paraformaldehyde for 20 minutes at room temperature, washed
with PBS, and blocked in PBS with normal goat serum for 1 hour
at room temperature. After blocking, cells were stained overnight
with primary antibody against Oct 4 (Clone C10, Santa Cruz
Biotechnology, Inc.) at a 1:100 dilution in PBS with 5% normal
goat serum and 0.02% Triton X-100 at 4uC. The next day, cells
were washed with PBS and stained with Alexa Fluor 555 goat anti-
mouse antibody (Invitrogen) at 1:400 dilution. After secondary
labeling, cells were washed in PBS and mounted in Prolong Gold
with DAPI.
Analysis of ALDH immunohistochemical staining
Quantification of ALDH expression was performed using
FRIDA (FRamework for Image Dataset Analysis; [39,40]), a
custom open source image analysis software package (available at
http://sourceforge.net/projects/fridajhu/) for the analysis of
RGB color images generated from scanning of tissue microarray
slides. Hue Saturation and Brightness (HSB) segmentation ranges
for DAB brown staining and hematoxylin alone (cells not staining
brown) were defined by creating different color masks. Numbers of
cells were counted by using particle count filter set with size
limitation. The percentage of ALDH+ cells were calculated by
using No. of DAB labeled cells divided by the sum of the DAB
labeled and the hematoxylin labeled cells 6100.
Soft agar colony formation
To test clonogenic activity, sorted ALDH
high or ALDH
low cells
from the TC71 cell line or from ESFT xenografts were seeded at a
density of 10
3 to 10
4 cells per well in 6 well plates (Corning Inc,
NY). Cells were cultured in 0.3% top agar (Invitrogen) prepared
from a 1:1 dilution of 0.6% bottom agar in RPMI-1640 medium
supplemented with 10% FBS. After 1 hour, top agar was
overlayed with 1 ml fresh media. Cells were maintained in a
37uC tissue culture incubator and after 2 weeks (6 weeks for cells
from xenografts) all colonies $20 cells were counted in duplicate
or triplicate wells using an inverted light microscope. To test the
drug sensitivity of colony formation, ALDH
high or ALDH
low cells
were plated at 50,000 cells/well and 24 hours later duplicate wells
were treated with doxorubicin (Sigma, St. Louis, MO) or YK-4-
279. After 2 weeks, colonies were stained with p-Nitro Blue
Tetrazolium Chloride (USB, Cleveland, OH) and scored by light
microscopy in 3 high powered fields/well. Colony size was
quantified using MCID Elite image analysis software (MCID,
Cambridge, UK).
Sphere formation
Sorted ALDH
high or ALDH
low cells obtained from the TC71
and MHH-ES cell lines or from the ESFT xenografts were
cultured in MesenCult (MSC Basal Medium) supplemented with
human MSC Stimulatory Supplements (Stem Cell Technologies,
Vancouver, BC). The indicated number of cells was seeded on
ultra low attachment plates (Corning, Inc, NY) in triplicate wells.
Spherical aggregates $16 cells were counted in individual wells
after 1 week (2 weeks for cells from xenografts).
In vivo tumorgenicity
Groups of 4–10 mice (six to eight week old NOG-SCID) were
injected with either sorted or unsorted cells subcutaneously into the
right flanks in a 1:1 mixture of Matrigel and HBSS in a final volume
of 200 ml. Mice were sacrificed when tumors reached 15 mm.
Figure 11. Efflux pumps may mediate relative chemoresistance of ALDH
high cells. (A) ALDH
high and ALDH
low TC71 cells were incubated
with Hoechst 33342 for 45 minutes, followed by a 45 minute wash out period. Average cellular fluorescence was quantified as relative fluorescence
units (RFU). Assay was performed in triplicate at least three times. Bars=SEM. (B) Unsorted TC71 cells, as well as ALDH
high and ALDH
low cells, were
incubated for 48 hours with 500 nM doxorubicin, 10 mM verapamil, or both. Surviving cells were quantified based on Trypan blue exclusion. Assays
were performed in triplicate at least three times. Bars=SEM. (C) Expression of EWS-FLI1 in ALDH
high cells as detected by RT-PCR. RNA was isolated
from ALDH
high, ALDH
low, and unsorted TC71 cells. RT-PCR was performed using primers specific for EWS-FLI1 and for ribosomal RNA 36B4 as a
positive control. Human myelomonocytic leukemia cell line U937 serves as a negative control.
doi:10.1371/journal.pone.0013943.g011
Figure 10. Relative chemoresistance of ALDH
high cells. Sorted ALDH
high and ALDH
low TC71, A4573, SK-ES-1, MHH-ES, and RD-ES cells, as well as
unsorted cells, were treated for 48 hours with increasing concentrations of either doxorubicin (left) or YK-4-279 (right). Surviving cells were quantified
based on their staining with DAPI but not PI. Experiments were performed in triplicate, and multiple independent FACS separations were analyzed. In
each panel, the red line is the survival curve for ALDH
high cells, the blue line is shows the ALDH
low cells, and the unsorted cells are represented by the
green line. Bars=SEM.
doi:10.1371/journal.pone.0013943.g010
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Sorted ALDH
high and ALDH
low TC71 cells were resuspended
at 10
6 cells/ml in RPMI-1640 medium containing 1% FBS and
were incubated with 5 mg/ml Hoechst 33342 dye (B2261,
bisBenzimide HOE 33342, Sigma-Aldrich) at 37uC for 45
minutes. Unincorporated dye was washed away using cold HBSS
containing 2% BSA at 4uC. Subsequently, the cells were
incubated in warm RPMI containing 1% FBS at 37uC for 45
minutes for dye efflux. Cells were centrifuged at 4uC and
mounted on glass slides in PBS for microscopy using Nikon
Eclipse Ti microscope. Photomicrographs were acquired imme-
diately and analyzed using Image J software (National Institutes
of Health, Bethesda, MD).
Chemosensitivity assays
Cell lines were labeled with Aldeflour reagent. ALDH
high and
ALDH
low cells were plated at similar density in RPMI-1640
medium with 10% FBS (2610
3 to 10
4 cells per well in 6 well
plates).After 24 hours, duplicate wells were treated with doxoru-
bicin or etoposide (Sigma, St. Louis, MO). In some experiments,
cells were also treated with 10 mM verapamil as an ABC
transporter protein inhibitor. After 48 hours, cells in individual
wells were collected, centrifuged and resuspended in 50 ml PBS.
To assess viability, cells were stained with 49,6-diamidino-2-
phenylindole (DAPI) and propidium iodide (PI). Cells staining with
DAPI and not PI were deemed viable and were counted.
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR) and qPCR
RNA was extracted from ALDH
high, ALDH
low or unsorted
TC71 cells using the RNeasy Mini Kit according to manufactur-
er’s instructions (QIAGEN Inc, Valencia, CA) reverse transcribed
as previously described (Iscript Reverse Transcriptase Bio-Rad,
Hercules, CA). For the PCR reaction we used Platinum Blue PCR
SuperMix (Invitogen, Grand Island, NY), 1 ml cDNA and 31
cycles of 94uC for 15 s, 60uC for 30 s, 72uC for 30 s. The PCR
product was separated by 1% agarose gel electrophoresis and
visualized with ethidium bromide. For quantitative PCR, 1 ml
cDNA was mixed with 12.5 ml SYBER Green SuperMix and
appropriate primers. Quantitative PCR was performed using a
standard two step amplification/melt protocol.
The EWS/FLI-1 primers were forward: TCCTACAGC-
CAAGCTCCAAGTC; reverse: ACTCCCCGTTGGTCCCC-
TCC. The oct-4 primers were as published by Liedtke et al [29].
Primers for bmi-1, nanog, and b2microglobulin were obtained from
SABiosciences (Frederick, MD).
Statistical Analysis
Differences in clonogenic activity and sphere formation between
ALDH
high and ALDH
low cells were tested for significance using a
two-sided t test. Differences in chemosensitivity were analyzed by
one-way ANOVA. All statistical analyses were performed with
Prism 4 software (GraphPad Software, Inc.).
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Figure 12. ALDH
high clonogenic activity is relatively resistant to doxorubicin but remains sensitive to EWS-FLI-1 inhibition. A)
ALDH
high and ALDH
low TC71 cells were plated at 50,000 cells per well on soft agar in the presence or absence of the indicated concentration of
doxorubicin. After 14 days, colonies were counted in 3 high power fields per well. Data represents average colony count from a representative
experiment done in duplicate wells. Bars=SEM. The asterisk (*) indicates conditions where the difference between ALDH
high and ALDH
low cells
reached statistical significance with a p value ,0.05. Representative images from ALDH
high (B 1 and 2) and ALDH
low (B3 and 4) colonies grown on soft
agar stained with crystal violet. Cells were treated with nothing (B1 and B3) or 200 nM doxorubicin (B2 and B4). Magnification: 1006. C and D)
Representative images from soft agar colony formation assay done in the presence of different doses of YK-4-279 are shown. ALDH
high (C) and
ALDH
low (D) TC71 cells were plated at 50,000 cells/well and treated with nothing or the indicated doses of the compound for 7 days. Magnification:
1006.
doi:10.1371/journal.pone.0013943.g012
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